The Biotech CEO Summit is designed to fully engage participants in thoughtful discussions around decisions and inflection points that many CEOs will encounter as they navigate through the challenges facing a biotech company in today’s environment. The topics are drawn from the participants themselves and from known events in the biotech community. This is unlike any other meeting for biotech CEOs.
Arrival & Registration
Biotech CEO Summit Opening Events
Conclusion of Opening Events
Breakfast
Welcome, Overview and Rules of Engagement
Discussion 1: Funding – Finding the Financing Strategy for Your Organization – trends, need to knows, and the real cost (Introduction of Pedestrian Oncology Case Study)
Morning Break
Discussion 2: Investor Relations – Understanding and Expanding Your Investor Base
Discussion 3: Strategy – It is Always Too Early to Plan For Commercialization Until It’s Too Late – Why and How You Should Think About It Now (Introduction of Lemur 1)
Networking Lunch
Discussion 4: Selecting Projects – There’s More Than Just The Science to Consider When Evaluating Which Assets Deserve Your Resources (Introduction of Lemur 2)
Discussion 5: Your Story – Vigilantly Developing and Communicating Your Story is a Key Tool That Drives Value
Unguarded Conversation Among CEOs & Friends – Speaking Up for Our Industry
Biotech CEO Summit Olympics
Wine Tasting
Artisanal Wine Tasting Reception & Networking Dinner
Hilltop Dining Room, The Carneros Inn
Breakfast of Champions
FARM Restaurant
Day 1 Recap
Strategy Discussion: Operating In A Competitive Environment Means You Have To Differentiate or Capitulate –
Payers have been bringing increasing pressure on the biopharma industry regarding price and pushing back on adding what they perceive as yet another ‘me too’ drug to their formularies. Being the third, fourth or fifth entry into a crowded field may have once been justified because even a small share of a large market is economically compelling. In today’s environment, however, a non-differentiated asset is just not good enough. When a lead asset has lost its advantage, a biotech CEO needs to rethink her/his strategy. Let’s consider the problem and an altered reality.
Morning Break
Relationships Matter –
Building solid relationships with a regulatory agency such as the FDA as well as other stakeholders, such as patient advocacy groups and the financial community, takes time and effort but is key to helping a CEO
lead his/her company through the challenges every biotech company will face.
Communications: Building Your Story –
Every biotech CEO is responsible for communicating the company’s vision through good times and bad. This leadership role involves managing challenges both internal – getting everyone on the same page – and external – managing perception among the financial community, the trade media, stakeholders, etc. The CEO needs to build consensus not only within his or her company, but, also must deliver the right message to the right constituency consistently.
Refuel & Refresh Networking Lunch
FARM Restaurant
A Brief Conversation with a Former Tech CEO
When Bad Things Happen To Good Companies –
Twenty years ago, the pharmaceutical industry ranked among the most respected of all industries; today they rank among the least admired – just above tobacco and financial companies. In the interim, while pharma became known for me-too statins and ED therapies, the biotechnology industry inherited the aura of the innovator of life saving therapies. Today, this aura is fading. It is no longer easy for a development stage company to stay beyond reproach. Even before a company enters the market, it may face recalcitrant regulators, issues about access or pricing, and stakeholders who are literally facing life or death outcomes. How can individual companies prepare themselves for maelstrom that may emerge when patients believe it is putting profits before patients?
Afternoon Break
An Unguarded Conversation Among Friends: The Characteristics Of Next Gen Outstanding Biotech CEOs
Wrap-up
Closing Reception
Carneros Courtyard
